No Data
H.C. Wainwright Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Cuts Target Price to $41
Cartesian Therapeutics Price Target Cut to $41.00/Share From $45.00 by HC Wainwright & Co.
Cartesian Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Oppenheimer Maintains Cartesian Therapeutics(RNAC.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC), Allogene Therapeutics (ALLO) and Moderna (MRNA)
Mizuho Securities Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Announces Target Price $40
No Data
No Data